Trials being done re efficacy of cannabis on AlZheimer'sIGC Announces IRB Approval of its IGC-AD1 for a Phase-2 Study BETHESDA, MD. September, 19, 2019 / India Globalization Capital, Inc. (NYSE: IGC) announced today that the Institutional Review Board (IRB), in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimers disease. With this important approval, our Company can implement a 50-person double-blind placebo-controlled trial that we hope begins to prove the efficacy of micro-doses of cannabis in combination with other natural compounds on the behavior of patients suffering from Alzheimers. We expect to measure improvements in neuropsychiatric symptoms (NPI) such as delusions, agitation/aggression, dysphoria, anxiety, sleep disorder, disinhibition, irritability, apathy and eating abnormalities, among others, stated Ram Mukunda, CEO. In 2017, IGC acquired a patent filing from the University of South Florida (USF) that showed that micro-doses of cannabis in combination with other natural compounds are beneficial to Alzheimers cell lines and to memory in transgenic mice.